Loading...
NPI 1023508223 · Honolulu, HI · Physiological Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Insight Imaging LLC is a physiological laboratory provider located in Honolulu, Hawaii. This profile covers 15 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Insight Imaging LLC |
| Address | 500 Ala Moana Blvd Ste 5b |
| City | Honolulu |
| State | HI |
| ZIP | 96813 |
| Taxonomy | Physiological Laboratory |
| NPI Enumerated | May 14, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $730.5K |
| Medicare | $452.6K |
INSIGHT IMAGING LLC’s billing mix is dominated by PET/CT and radiopharmaceutical diagnostic services, with the leading Medicare and Medicaid codes being 78815 (PET/CT), A9596 (Ga-68 diagnostic), and A9552 (F-18 FDG diagnostic). The descriptions for these codes indicate an operation focused on oncologic and metabolic imaging rather than broad multispecialty imaging, emphasizing tracer-based nuclear medicine studies and fused PET/CT exams as core services. This code mix points to a specialized imaging center model that relies on radiopharmaceutical supply and PET/CT scanning throughput.
Revenue concentration is very high on Medicare: the precomputed top-3 Medicare codes account for 86.6% of the provider’s total Medicare revenue, and those three codes are 78815 (46.3% of Medicare revenue), A9596 (26.6%), and A9552 (13.7%) within a total Medicare revenue pool of $452.6K. Such concentration means Medicare income is largely dependent on a small set of high-value PET/CT and tracer codes.
On Medicaid the concentration is even more extreme: the precomputed top-3 Medicaid codes account for 99.9% of the provider’s total Medicaid revenue, with 78815 generating $526.3K (72.1% of Medicaid revenue) and A9552 generating $202.2K (27.7%) out of total Medicaid revenue of $730.5K. Medicaid billing therefore overwhelmingly reflects PET/CT and FDG tracer studies, making the provider effectively single-service-line focused within the Medicaid population.
The payer mix is skewed toward Medicaid in scale: total Medicaid revenue of $730.5K exceeds Medicare revenue of $452.6K, so this provider is more Medicaid-driven in overall billed revenue while still maintaining a sizable Medicare PET/CT business. This means changes in Medicaid reimbursement or network position in-state could have a larger dollar impact on the practice than parallel Medicare shifts.
Competitive standing is modest nationally but relatively prominent within the small in-state peer set: on Medicare the provider’s volume for 78815 ranks #1377 of 6566 (79th percentile) and is labeled as "typical, unremarkable volume," while A9552 ranks #463 of 2411 (81st percentile), indicating nationally it is a typical-sized participant rather than a dominant national center. On Medicaid, 78815 ranks #3 of 5 in-state (50th percentile) and A9552 ranks #2 of 5 (75th percentile), so within Hawaii’s very small peer group the practice is one of only a handful of PET/CT suppliers and shows relatively stronger positioning on FDG.
Operational detail and claim patterns show high Medicaid claim counts for key tracers (78815: 867 claims, A9552: 991 claims) compared with the Medicare claim counts for the same codes (78815: 150 claims, A9552: 145 claims), reinforcing that the provider treats a larger volume of Medicaid patients for PET imaging. Additionally, the Medicare file lists Q9967 with 5.3K claims and $0 revenue, ranked #4546 of 11759 (61st percentile), which appears as a high-frequency supply/contrast line with no paid amount on file and may reflect pass-through or billing artifact rather than revenue contribution.
The provider has relatively recent tenure: NPI enumerated 2018-05-14 (~8 years ago), indicating roughly eight years of enrollment during which it established a concentrated PET/CT and radiopharmaceutical practice. This timeframe is consistent with developing a focused imaging center rather than a long-established, highly diversified radiology group.
Given the extreme revenue concentration on a narrow set of PET/CT and radiopharmaceutical codes across both payers, the practice has limited service diversification and therefore faces concentration risk: reimbursement changes, supply pricing shifts for tracers, or local competition in PET/CT could materially affect revenue. The data support monitoring tracer reimbursement and in-state market moves as primary risk factors for this provider’s financial profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 150 | $1,400 | $209.3K |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 150 | $790 | $120.2K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 150 | $430 | $62.1K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 20 | $1,360 | $31.3K |
| 74178 | The provider performs computed tomography of the abdomen and pelvis without contrast material in one or both body regions followed by contrast material in one or both body regions and additional… | 30 | $270 | $6.8K |
| 76770 | A retroperitoneal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e.Kidneys, urinary bladder, and aorta). This particular code is used when the ultrasound is… | 60 | $80 | $4.3K |
| 74177 | The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs. | 20 | $260 | $3.9K |
| 93970 | The provider performs an ultrasound scanning procedure called a duplex scan to characterize the pattern and direction of blood flow in extremity veins (arms or legs). This is a complete, bilateral… | 20 | $170 | $3K |
| 76700 | An abdominal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e. liver, gallbladder, pancreas, bile ducts, spleen, and abdominal aorta). This particular code… | 30 | $90 | $2.4K |
| 93971 | The provider performs an ultrasound scanning procedure called a duplex scan to characterize the pattern and direction of blood flow in extremity veins (arm or leg). This is a unilateral or limited… | 20 | $100 | $2.2K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 870 | $610 | $526.3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 990 | $200 | $202.2K |
| 76700 | An abdominal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e. liver, gallbladder, pancreas, bile ducts, spleen, and abdominal aorta). This particular code… | 10 | $70 | $780 |
| 76705 | An abdominal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e. liver, gallbladder, pancreas, bile ducts, spleen, and abdominal aorta). This particular code… | 20 | $30 | $510 |
| S9999 | Sales tax | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 3 | 10 | 870 | $780 | $981.5K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2 | 10 | 790 | $120 | $105.7K |
| 76700 | An abdominal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e. liver, gallbladder, pancreas, bile ducts, spleen, and abdominal aorta). This particular code… | 23 | 20 | 250 | $70 | $60.5K |
| 76705 | An abdominal ultrasound is a noninvasive procedure used to assess the body parts within the abdomen (i.e. liver, gallbladder, pancreas, bile ducts, spleen, and abdominal aorta). This particular code… | 22 | 20 | 880 | $30 | $45.3K |
| S9999 | Sales tax | 212 | 240 | 200 | $1 | $820 |
Other providers in the same ZIP code as Insight Imaging LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.